Radiopharmaceutical developer Blue Earth Diagnostics said that Northside Hospital in Atlanta is the first institution to perform a commercial administration of its Axumin PET radiopharmaceutical.
Axumin, which contains a fluciclovine amino acid labeled with an F-18 radioisotope, was approved by the U.S. Food and Drug Administration (FDA) in May for use in patients with suspected recurrent prostate cancer. It's now also being used commercially at other medical centers, Blue Earth said.
The PETNet Solutions subsidiary of Siemens Healthineers is distributing Axumin through its national radiopharmacy network. Blue Earth noted that initial commercial production of Axumin is underway at certain regional pharmacies, with broader availability planned over the coming months.
